Follow us on Twitter
twitter icon@FreshPatents


Expression Vector patents

      

This page is updated frequently with new Expression Vector-related patent applications.




 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase patent thumbnailMethod for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
The present invention relates to a novel function of lysyl trna synthetase, that is, lysyl trna synthetase interacts with 67lr through translocation of krs into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl trna synthetase, an use of an expression vector comprising a construct inhibiting krs expression for preventing or treating cancer, an use of an agent inhibiting krs activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between krs and 67lr.
Medicinal Bioconvergence Research Center


 E1 enzyme mutants and uses thereof patent thumbnailE1 enzyme mutants and uses thereof
The invention provides isolated nucleic acids molecules, designated uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, which encode novel e1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a uba3, uae, or uba6, or other e1 enzyme variant gene has been introduced or disrupted.
Millennium Pharmaceuticals, Inc.


 Anti-vasa antibodies, and methods of production and use thereof patent thumbnailAnti-vasa antibodies, and methods of production and use thereof
Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.


 Cellular vaccine and  inducing an immune response in a subject patent thumbnailCellular vaccine and inducing an immune response in a subject
The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd.


 Enzymatic synthesis of optically active chiral amines patent thumbnailEnzymatic synthesis of optically active chiral amines
The present invention relates to a method of enantioselective enzymatic transamination of (1r)-1-hydroxy-1-phenylacetone (r-pac) to a chiral amine 1r, 2s-norephedrine in the presence of an isopropylamine catalyzed by enantioselective transaminase. Isopropylamine is converted to acetone in the process.
Embio Limited


 Methods for reprogramming cells and uses thereof patent thumbnailMethods for reprogramming cells and uses thereof
An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: musashi1 (msi1); ngn2; msi1 and ngn2; msi1 and methyl-cpg binding domain protein 2 (mbd2); ngn2 and mbd2; msi1, ngn2 and mbd2; achaete-scute homolog 1 (ascl1); msi1, ngn2 and ascl1; msi1, ngn2, mbd2 and ascl1; sox2; msi1, ngn2 and sox2; and msi1, ngn2, mbd2 and sox2; wherein the expression vector is transiently expressed.. .
Genesis Technologies Limited


 Methods and compositions comprising human recombinant growth and differentiation factor-5 (rhgdf-5) patent thumbnailMethods and compositions comprising human recombinant growth and differentiation factor-5 (rhgdf-5)
expression vector systems are provided for increased production of a recombinant gdf-5 (rhgdf-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhgdf-5 protein.
Warsaw Orthopedic, Inc.


 Transgenic tobacco plants for enhanced bioethanol production patent thumbnailTransgenic tobacco plants for enhanced bioethanol production
Genetically modified tobacco plants are provided having altered hexose accumulation. Methods are provided for producing ethanol from fermentation of tobacco biomass derived from the tobacco plants having altered hexose accumulation.
Tyton Biosciences, Llc


 Eukaryotic expression vectors resistant to transgene silencing patent thumbnailEukaryotic expression vectors resistant to transgene silencing
The present invention relates to recombinant dna molecules such as plasmids, non-viral vectors, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said dna molecules in cell lines and organisms.. .
Nature Technology Corporation


 Vectors and methods for fungal genome engineering by crispr-cas9 patent thumbnailVectors and methods for fungal genome engineering by crispr-cas9
The present disclosure provides expression vectors containing a nucleic acid encoding an rna polymerase iii promoter, a ribozyme, a crispr-cas9 single guide rna, and an rna polymerase iii terminator, where the ribozyme is 5′ to the crispr-cas9 single guide rna, as well as ribonucleic acids encoded thereby. Further provided are fungal cells containing an expression vector described herein, as well as methods of fungal genome engineering through use of an expression vector described herein..
Bp Corporation North America Inc.


Monoclonal antibodies to programmed death 1 (pd-1)

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.

Delivery of nrf2 as therapy for protection against reactive oxygen species

The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating nrf2 to a subject in need thereof..
University Of Florida Research Foundation, Inc.

Composition for improving skin conditions comprising a fragment of human heat shock protein 90a as an active ingredient

Liposomal and/or nano-liposomal encapsulated hsp90a, hpf polypeptide (115 aa) and novel polypeptides hpf Δc1 (101 aa) and hpfΔc2 (87 aa), as well as methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include an hsp90a, hpf-polypeptide, hpf Δc1 or hpfΔc2 polypeptide are presented.
Regeron, Inc.

Novel polypeptide binding to extracellular domain of epidermal growth factor receptor

The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor.
Korea Advanced Institute Of Science And Technology

Anti-pd-1 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to human pd-1 and antagonize pd-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies..
Memorial Sloan Kettering Cancer Center

Rtef-1 variants and the use thereof for inhibition of angiogenesis

Dominant negative (dn) variants of transcriptional enhancer factor 1-related (rtef-1) are described. Dn rtef-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription.
Research Development Foundation

Systems and methods for nucleic acid expression in vivo

The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are cpg-free or cpg-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules..
Dnarx

Modified coagulation factor viia with extended half-life

The present invention relates to the fields of factor vii (fvii) and factor viia (fviia) albumin linked polypeptides. More specifically, the invention relates to cdna sequences coding for human factor vii and factor viia and derivatives genetically fused to a cdna coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cdna sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives.
Csl Behring Gmbh

Anti-kit antibodies and uses thereof

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation.
Kolltan Pharmaceuticals, Inc.

Enhanced production of recombinant crm197 in e. coli

Rediced genome or native k12 strain e. Coli bacteria comprising expression vectors encoding a recombinant crm197 protein and their use in the production of crm 197 is provided.
Scarab Genomics, Llc

Enhancing serological assays via fusion proteins

A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
Cornell University

Parainfluenza virus 5 based vaccines

The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (piv5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.. .
University Of Georgia Research Foundation, Inc.

Expression vector system comprising two selection markers

Wherein the activity of the selectable marker (sm i) or (sm ii) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm i) and (sm ii) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield..

Novel fatty acid desaturases and elongases and uses thereof

The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturases and elongases from the organism emiliana huxleyi. The invention also provides recombinant expression vectors containing desaturase or elongase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (lcpufas), e.g.
Basf Plant Science Company Gmbh

Monoclonal antibodies that neutralize a norovirus

Monoclonal neutralizing antibodies are disclosed that specifically bind to a norovirus. In some embodiments, the norovirus is a genogroup ii norovirus or a genogroup ii norovirus.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Novel insulin analogs and use thereof

The present invention relates to a novel insulin analog, and more specifically, to an insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.. .
Hanmi Pharm. Co., Ltd.

Human antibodies that bind cd22 and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to cd22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.

Lung-targeting nanobodies against human pulmonary surfactant protein a and a producing the same

The present invention relates to the field of biochemistry and pharmaceutical technologies. The present invention provides nanobodies that bind to human pulmonary surfactant protein a (sp-a) as well as the preparing methods and use of the same.
Shanghai Pulmonary Hospital

Modified pseudomonas exotoxin a

The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
Hoffmann-la Roche Inc.

Nonribosomal peptide synthetases

The present disclosure is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (nrps) derived drug and analogs thereof. The invention provides polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the nrps-derived drug, the polypeptides encoded by such polynucleotides, expression vectors comprising the polynucleotides, host cells comprising the polynucleotides or expression vectors, and kits comprising a host cell.
Regents Of The University Of Michigan

Biomolecule-releasing cell and selection thereof by means of a surface protein

The invention relates, firstly, to a biomolecule-releasing cell characterised by a surface protein with an extracellularly exposed ligation peptide sequence for enzymatic conjugation of an adapter ligand, said adapter ligand being suitable for the indirect or direct coupling of a molecular catcher structure which has at least one specific binding site for the released biomolecules and which is at a distance from the specific binding site, secondly, to a method for selecting such a cell, and thirdly, to a means for this method comprising the surface protein that is characterised by an extracellularly exposable ligation peptide sequence for enzymatic conjugation of an adapter ligand, a nucleic acid coding for the surface protein, an expression vector for the nucleic acid, and a cell containing the expression vector.. .
New/era/mabs/gmbh

Fusion proteins, polynucleotides, expression vectors, and their uses

Provided are fusion proteins, polynucleotides and expression vectors with therapeutic utility in the prevention and/or treatment of cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of trail, and a membrane-anchoring amino acid sequence.
The University Of Liverpool

A protein secretory factor with high secretory efficiency and an expression vector comprising the same

The present invention relates to a novel protein secretion factor, a vector including a nucleic acid sequence encoding the protein secretion factor, and a transformed cell into which the vector is introduced. The invention also relates to a method of producing a target protein using the transformed cell including the vector..
Lg Life Sciences Ltd.

Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (psma) are provided. The modified anti-psma antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human.

Construct and sequence for enhanced gene expression

The invention relates to a method for transcription and expression using a nucleic acid construct which is characterized by the presence of a promoter followed by an intronic promoter. The invention further relates to said nucleic acid construct, an expression vector and a cell comprising said construct, and its use.
R1 B3 Holding B.v.

Methods for reprogramming cells and uses thereof

An in vitro human cardiac multi potent or unipotent cell that has the ability to proliferate; may be maintained in standard cardiac stem cell media; can differentiate to a progenitor, precursor, or somatic cell; has the characteristics of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; does not exhibit uncontrolled growth, teratoma formation, or tumor formation in vivo; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; and is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; wherein the cell comprises at least one transiently expressed polypeptide or an expression vector.. .
Genesis Technologies Limited

Pdgf receptor beta binding polypeptides

The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human pdgfrβ) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides.
X-body, Inc.

Human tim-3 fusion protein capable of blocking tim-3 signaling pathway

The present invention provides a human tim-3-ig fusion protein which can block tim-3 signal pathway, and said ig fusion protein comprises tim-3 protein, human ig fragment, and the linking sequence therebetween. In the present invention, a human tim-3-ig gene is obtained by an artificial synthesis process; an expression vector containing the tim-3-ig gene is constructed; and the prepared ig fusion protein is tested in an expression verification experiment, a binding activity experiment, a blocking activity experiment in different cell lines, and in vivo experiments in mice.
Institute Of Basic Medical Science Of Military Medical Science Of The Chinese Pla

Murine anti-ny-eso-1 t cell receptors

The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

A modified mglur6 promoter and methods of use

The invention provides nucleic acids and nucleic acid expression vectors containing optimized mglur6 promoters for expression of transgenes in the retina. The compositions and methods of the invention are useful for expression of gene products to preserve, improve, or restore phototransduction or vision..
Wayne State University

Superagonists and antagonists of interleukin-2

Novel human interleukin-2 (il-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed.
The Board Of Trustees Of The Leland Stanford Junior University, Office Of The General Counsel

Materials and methods for producing cleaved, hiv-1 envelop glycoprotein trimers

Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of hiv-1 envelope proteins, including sosip modified gp140 trimers capable of inducing broadly neutralizing antibodies.. .
Cornell University

Mucin antigen vaccine

Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
Microvax, Llc

Vectors and strains for producing myrcene and producing myrcene using the same

Disclosed herein are an expression vector capable of expressing myrcene, an escherichia coli strain transformed with the vector and having improved capability of producing myrcene and a method for producing myrcene and a method for recycling glycerol using the same. In an aspect, the transformed escherichia coli strain of the present disclosure can produce myrcene with high purity on a large scale using glycerol or glucose as a carbon source.
Korea Institute Of Science And Technology

Methods and compositions for gene delivery to on bipolar cells

Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye.
University Of Florida Research Foundation, Inc.

Novel insecticidal proteins and methods for their use

Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
E. I. Du Pont De Nemours And Company

Methods for determining modulators of insect transient receptor potential v (trpv) channel

The present invention relates to a screening method for determining whether or not a candidate compound is a modulator of an insect transient receptor potential v (trpv) channel. The present invention further provides a method of insect control by applying to an insect-specific trpv channel modulator determined by the screening method.
Basf Se

Novel insecticidal proteins and methods of use

Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred International, Inc.

Vectors for use in an inducible coexpression system

The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product.. .
Absci, Llc

Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction rna interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide gag repeats

Subjects of the invention are: nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of rna interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide cag-type repeats. Solution relates to the new concept of treating hereditary human neurological diseases caused by expansion of cag-type trinucleotide repeats using rna interference technology..
Instytut Chemii Bioorganicznej Pan

Improved raav vectors and methods for transduction of photoreceptors and rpe cells

Disclosed are capsid-modified raav particles and expression vectors, as well as compositions and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and using novel capsid-protein-mutated particle or raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye.
University Of Florida Research Foundation, Inc.

Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof

The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturase family members. The invention also provides recombinant expression vectors containing desaturase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (lcpufas), e.g., dha..
Bioriginal Food & Science Corp

Dna polymerase possessing continuous catalytic capacity and salt tolerance

A dna polymerase, having an amino acid sequence represented by seq id no. 2, or a derivative of the amino acid sequence by substitution, deletion, or addition of at least one amino acid residue.
Biotechnology Research Institute, Chinese Academy Of Agricultural Sciences



Expression Vector topics:
  • Expression Vector
  • Recombinant
  • Nucleic Acid
  • Antibodies
  • Polypeptide
  • Amino Acid
  • Amino Acid Sequence
  • Nucleic Acids
  • Polynucleotide
  • Nucleotide
  • Cytomegalovirus
  • Endothelial
  • Extracellular
  • Endothelial Cell
  • Epithelial


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.1573

    file didn't exist2806

    479197 - 0 - 53